Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24324149 | 1.00 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2GAACASR | |
| SCHEMBL1769068 | 1.00 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2GAACASR | |
| SCHEMBL8231488 | 0.87 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL27734524 | 0.87 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL28212893 | 0.85 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL5076672 | 0.84 | LMNA (0.56) | NPC1RAB9AGAACASR | |
| SCHEMBL5076667 | 0.84 | LMNA (0.56) | NPC1RAB9AGAACASR | |
| SCHEMBL1768708 | 0.84 | CYP1A2 (0.55) | RAB9ASMN1; SMN2 | |
| SCHEMBL24324163 | 0.84 | CYP1A2 (0.55) | RAB9ASMN1; SMN2 | |
| SCHEMBL1768705 | 0.84 | CYP1A2 (0.55) | RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2018204764-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION (US) | 2018-11-08 | — | — | WO | disclosed |
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050080119-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2005-04-14 | — | — | US | disclosed |
| US-6803384-B2 | FOR THERAPY OF REPERFUSION INJURY | HOFFMANN-LA ROCHE INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040006236-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2004-01-08 | — | — | US | disclosed |
| US-20020052512-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER (US) | 2002-05-02 | — | — | US | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | NPC1 2647/4885RAB9A 1699/4885SMN1; SMN2 1582/4885 |
| US-20040006236-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | NPC1 2397/4885RAB9A 2103/4885SMN1; SMN2 1708/4885 |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | NPC1 1872/4885RAB9A 1588/4885SMN1; SMN2 2326/4885 |
| US-20020052512-A1 | Diaminopropionic acid derivatives | AIFM1, AIFM2, HIF1A | NPC1 2397/4885RAB9A 2103/4885SMN1; SMN2 1708/4885 |
| US-20070155671-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | NPC1 2646/4885RAB9A 2133/4885SMN1; SMN2 2102/4885 |
| US-20050080119-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | NPC1 2646/4885RAB9A 2133/4885SMN1; SMN2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.